Pfizer Inc. $PFE Shares Sold by Lawson Kroeker Investment Management Inc. NE

Lawson Kroeker Investment Management Inc. NE trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 1.1% during the second quarter, Holdings Channel reports. The firm owned 207,651 shares of the biopharmaceutical company’s stock after selling 2,275 shares during the quarter. Lawson Kroeker Investment Management Inc. NE’s holdings in Pfizer were worth $5,033,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Sippican Capital Advisors grew its stake in shares of Pfizer by 37.4% in the second quarter. Sippican Capital Advisors now owns 92,912 shares of the biopharmaceutical company’s stock valued at $2,252,000 after buying an additional 25,285 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its holdings in Pfizer by 26.4% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 504,446 shares of the biopharmaceutical company’s stock valued at $12,230,000 after acquiring an additional 105,453 shares during the period. Concurrent Investment Advisors LLC boosted its holdings in Pfizer by 11.5% during the 2nd quarter. Concurrent Investment Advisors LLC now owns 200,775 shares of the biopharmaceutical company’s stock valued at $4,867,000 after acquiring an additional 20,663 shares during the period. Inman Jager Wealth Management LLC grew its position in Pfizer by 14.7% in the 2nd quarter. Inman Jager Wealth Management LLC now owns 40,084 shares of the biopharmaceutical company’s stock valued at $972,000 after acquiring an additional 5,124 shares in the last quarter. Finally, Fifth Third Wealth Advisors LLC increased its stake in Pfizer by 20.6% during the second quarter. Fifth Third Wealth Advisors LLC now owns 145,041 shares of the biopharmaceutical company’s stock worth $3,516,000 after purchasing an additional 24,756 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the subject of several recent research reports. Morgan Stanley lowered their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Citigroup upped their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Finally, UBS Group reiterated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $28.35.

Pfizer Trading Down 1.7%

Shares of NYSE:PFE opened at $24.81 on Friday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $29.82. The company’s 50 day moving average is $24.86 and its two-hundred day moving average is $24.13. The company has a market cap of $141.03 billion, a PE ratio of 13.19, a P/E/G ratio of 0.81 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. Pfizer’s dividend payout ratio is presently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.